AGRX (Agile Therapeutics) Total Current Assets : $14.44 Mil (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Agile Therapeutics's total current assets for the quarter that ended in Jun. 2024 was $14.44 Mil.

Agile Therapeutics Total Current Assets Historical Data

The historical data trend for Agile Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics Total Current Assets Chart

Agile Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

35.32

56.79

23.93

11.36

9.53

Agile Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Current Assets	Get a 7-Day Free Trial															11.65	10.06	9.53	11.99	14.44

Agile Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Agile Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.557	+	3.392	+	2.738	+	0.843
	=	9.53

Agile Therapeutics's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.848	+	4.55	+	5.793	+	1.252
	=	14.44

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Agile Therapeutics (OTCPK:AGRX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Agile Therapeutics's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.848	-	36.875	+	0.75 * 4.55	+	0.5 * 5.793
=	-27.72

Agile Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Agile Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 College Road East, Suite 310, Princeton, NJ, USA, 08540

Website

https://www.agiletherapeutics.com

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Executives

Scott M Coiante	officer: Chief Financial Officer	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente	director	101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh	officer: Chief Commercial Officer	500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari	director, officer: Chief Executive Officer	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly	officer: Chief Financial Officer	600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch	officer: Principal Accounting Officer	101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner	officer: Sr. VP & Chief Medical Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele	director, See remarks	C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003